Home MarketDivi's Laboratories Ltd.

Divi's Laboratories Ltd. Stock Info: As on 2018-05-24 15:52:29

Nse

1128.70

35.35(3.23%)
Change%
52 Week Range
532.65
29.00
1,223.00
11.00
Open1,093.10
Day's Range984.02 - 1,202.69
Value Traded (in ₹ Cr.) 50.71

Bse

1127.30

34.55(3.16%)
Change %
52 Week Range
533.10
29.00
1,220.00
11.00
Open1,092.65
Day's Range983.48 - 1,202.03
Value Traded (in ₹ Cr.) 2.10

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 138,181,232.00 52.05%
Mutual Funds/UTI 41,025,312.00 15.45%
FII 48,862,026.00 18.41%
Employee 0.00 0.00%
Public 22,366,479.00 8.43%
Government 0.00 0.00%
Others 14,195,270.00 5.35%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.12
Basic EPS (Rs.) 39.68
Cash EPS 44.32
BVPerShare Excl 203.75
Operating Revenue 151.58
PBDITPerShare 57.02
Dividend 10.00
NPPerShare 39.68
Current Ratio 6.16
Quick Ratio 4.24
PriceToBV 3.06
Earnings 0.06
PBDIT Margin 37.61
PBT Margin 34.49
NP Margin 26.17
Return On Assets 16.96
Retention Ratios 0.00
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 4,099.83
Total Expenses 2,711.60
EBITDA 1,513.75
PBT 1,388.23
PAT 1,053.27
Net Income 1,053.27
More
Parameter Sep-17 (₹ Cr.) 6M % change
Total Income 1,774.67
Total Expenses 1,255.62
EBITDA 452.81
PBT 517.81
PAT 383.32
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 53.09
Net worth 5,408.91
Investments 1,639.09
Total Liability 6,210.08
Total debt 35.74
Net block 2,002.53
Total Assets 6,210.08
Parameter Sep-17 (₹ Cr.) 6M % change
Total share capital 53.09
Net worth 4,100.87
Investments 662.79
Total Liability 4,761.28
Total debt 36.68
Net block 1,590.62
Total Assets 4,761.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 1,148.05
Cash from investing activities -1,134.08
Cash from financing activities -9.31
Net change in cash 4.66

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Equity Hybrid Fund 2.35%
Reliance Multi Cap Fund 4.76%
SBI Blue Chip Fund 1.78%
Reliance Large Cap Fund 2.82%
HDFC Mid-Cap Opportunities Fund - Regular Plan 1.18%
Reliance Pharma Fund 11.76%

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Divi's Lab surges 4% on successful USFDA inspection at Choutuppal unit

Shares of Divi's Laboratories jumped over 4 per cent on the Bombay Stock Exchange after the company said that the inspection conducted by the United States Food and Drug Administration (US-FDA) of its Unit-1 facility at Choutuppal, Telangana this month was successful. Cheering the news, stocks of the company gained as much as 4.01 per cent and touched an intra-day high of Rs 1213.00 apiece on the Bombay Stock Exchange. In a similar trend, shares of the firm were trading 0.89 per cent higher at Rs 1,175.50 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 35,263.69, down 124.19 points, or 0.35 per cent at 13:00 hours.

17-May-2018 12:58 PM

Divi's Labs Telangana unit completes USFDA inspection with no observations

Divi's Laboratories today said its unit at Choutuppal in Telangana has undergone successful inspection by the US health regulator with no observations. The company's unit-I at Choutuppal has had an inspection by the United States Food and Drug Administration (USFDA) from May 14-16, 2018, Divi's Labs said in a filing to BSE. This was a general cGMP inspection by USFDA. The inspection has been concluded with no 483 observations, it added. As per USFDA, form 483 observations are issued after conclusion of inspection to notify the company's management of objectionable conditions at its facility.

16-May-2018 05:56 PM

Divi's Lab - Announcement Under Regulation 30 (LODR) Updates- US-FDA Inspection Of Unit-I At Choutuppal, Telangana State

Divi's Laboratories hereby announces that its Unit-I at Choutuppal, Telangana State has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations.

16-May-2018 04:33 PM

Divi's Lab - Updates

Divi''s Laboratories Limited has informed the Exchange regarding ''Divi?s Laboratories hereby announces that its Unit-I at Choutuppal, Telangana State has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations.''.

16-May-2018 04:32 PM

Divi's Lab - Board to consider FY18 results & Dividend on May 26, 2018

Divis Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be held on May 26, 2018, inter-alia, to consider and approve standalone and consolidated audited financial results for the year ended March 31, 2018 and to recommend dividend, if any, on Equity Shares for the financial year 2017-18.

Further, the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from May 19, 2018 to May 28, 2018 (both days inclusive) as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

16-May-2018 02:26 PM

Divi's Lab - Announcement Under Regulation 30 (LODR) Updates- US-FDA Inspection Of Unit-I At Choutuppal, Telangana State

Divi's Laboratories hereby announces that its Unit-I at Choutuppal, Telangana State has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations.

16-May-2018 04:33 PM

Divi's Lab - Board to consider FY18 results & Dividend on May 26, 2018

Divis Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company is scheduled to be held on May 26, 2018, inter-alia, to consider and approve standalone and consolidated audited financial results for the year ended March 31, 2018 and to recommend dividend, if any, on Equity Shares for the financial year 2017-18.

Further, the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from May 19, 2018 to May 28, 2018 (both days inclusive) as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

16-May-2018 02:26 PM

Divi's Lab - Board Meeting On 26/05/2018

Notice is hereby given that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, the 26th day of May 2018, inter-alia, to consider and approve standalone and consolidated audited financial results for the year ended 31st March 2018 and to recommend dividend, if any, on Equity Shares for the financial year 2017-18.

We further inform you that the Trading Window for dealing in securities of the Company shall remain closed for insiders of the company from May 19, 2018 to May 28, 2018 (both days inclusive) as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

16-May-2018 02:18 PM

Corporate Details

About Management

Milestones: 1990 -Divis Research Center (DRC) established. 1991-1993 -DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. 1994 -Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year. 1995 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations. 1997 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant. 1999 -European Directorate gives a "Certificate of Suitability" (CoS) for Naproxen produced at Divis Laboratories. 2000 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems). 2001 -BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems). 2002 -Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam. 2003 -Divis opens a new research center christened `DRC-Vizag' for fundamental research in selected niche business core segments. -Went for IPO and listed on stock exchanges BSE, NSE and HSE. -Divi's Laboratorie receives Certificate of Substantiability from the council of Europe -Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization. 2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004. -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 2006 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006. -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 2007 - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Third US-FDA inspection for Choutuppal(Unit-1). 2009 - Certified and Awarded for "Best Green Belt Development" - SURAKSHA PURASKAR for the year 2008 - ISO 14001: 2004 (Re-Certification) "Environment Management System" -Divi's Laboratories has given the Bonus in the Ratio of 1:1 2010 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam. - The Company has recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010. 2011 - Divi’s Laboratories surged 3.5 per cent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours. - Shares of the company after opening higher at Rs 765 from previous close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE, reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was trading at Rs 772.85 on Bombay Stock Exchange. 2012 - Divis Laboratories Ltd has informed BSE that the Board of Directors through Circular resolution dated March 07, 2012 has decided to seek shareholders approval by postal ballot for Re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company. - The Company Re-appointment and revision in remuneration of Mr. Kiran S. Divi Director & President- Operations of the Company. - Enhancement of remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company. - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director of the Company. 2013 -Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013. 2014 -Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014. 2015 -Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1. 2016 -Divis Labs unit-2 at Chippada successfully inspected by USFDA

Registered Office

DSN SEZ Unit : Chippada Village, Bheemunipatnam Mandal,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.